Oritavancin

Related by string. oritavancin * * oritavancin semi . commercialize oritavancin *

Related by context. All words. (Click for frequent words.) 74 Vitro Activity 73 Radezolid 72 Ceftaroline 70 Antiviral Activity 69 Cethromycin 69 Clinical Trial Results 69 Bortezomib 69 Anti Tumor 69 Dalbavancin 69 Telbivudine 68 Golimumab 68 Pafuramidine 68 delafloxacin 68 Aliskiren 68 Epidermal Growth Factor Receptor 68 Phase 2b Clinical Trial 68 sunitinib Sutent ® 68 tigecycline 68 Universal Flu Vaccine 68 BAL# [001] 68 Pharmacokinetics PK 68 Demonstrates Potent 68 JAK Inhibitor 67 Boceprevir 67 Tesetaxel 67 investigational humanized monoclonal antibody 67 solithromycin 67 Sapacitabine 67 Cytotoxicity 67 BAL# [002] 67 Investigational Drug 67 Maribavir 67 Linezolid 67 Dasatinib 67 Pivotal Phase III 67 Pathway Inhibitor 67 Kinase Inhibitor 67 Phase III Clinical Trial 67 oral prodrug 67 Perifosine 66 liposomal formulation 66 Phase IIb Trial 66 Meets Primary Endpoint 66 radezolid 66 Tyrosine Kinase Inhibitor 66 non nucleoside inhibitor 66 Monoclonal Antibody 66 Capecitabine 66 fusidic acid 66 Metastatic Melanoma 66 T#I [002] 66 Pegylated 66 Liposomal 66 Carfilzomib 66 Investigational Compound 66 CYC# 66 Bosutinib 66 Fidaxomicin 66 Phase 2a Clinical Trial 66 Tezampanel 66 Vaccine Candidate 66 NS#/#A protease 66 Phase IIb Clinical Trial 66 Thiovir 66 Antiangiogenic 66 ACHN 66 Ambrisentan 66 EZN 66 Epratuzumab 66 Aurora Kinase 66 Peginterferon 66 Randomized Phase 66 Irinotecan 66 Tigecycline 66 Antitumor Activity 66 Denufosol 66 Monotherapy 65 Interferon Gamma 65 Enzastaurin 65 HDAC Inhibitor 65 Oral Fingolimod 65 Infected Patients 65 Anti Tumor Activity 65 Phase 2b Trial 65 Fungal Infections 65 Pharmacokinetic Study 65 Unfractionated Heparin 65 torezolid 65 Novel Oral 65 Traficet EN 65 Hsp# Inhibitor 65 pan HDAC inhibitor 65 Sym# 65 Daptomycin 65 Valortim R 65 Immunogenicity 65 Dose Ranging Study 65 Ramoplanin 65 Drug Candidate 65 fosbretabulin 65 Ecallantide 65 Nilotinib 65 Fulvestrant 65 antibody MAb 65 humanized monoclonal 65 Omacetaxine 65 Antiviral Therapy 65 imatinib Gleevec ® 65 micafungin 65 PRTX 65 Combination Therapy 65 Chemokine Receptor 65 Placebo Controlled Trial 65 Pooled Analysis 65 dasatinib Sprycel ® 65 Phase IIa Clinical Trial 65 Prolongs Survival 65 Therapeutic Vaccine 65 Dendritic Cells 65 Well Tolerated 65 meropenem 65 Low Dose 65 Factor VIIa 65 Interferon Beta 65 mapatumumab 64 Interferon alfa 64 Protease Inhibitor 64 sodium glucose cotransporter 64 Oral Insulin 64 liposomal amphotericin B 64 Pralatrexate 64 Pioglitazone 64 Adefovir 64 Tipranavir 64 Decitabine 64 Preclinical Data 64 Phase III Clinical Trials 64 RNAi Therapeutic 64 Valopicitabine 64 orally administered inhibitor 64 Imatinib 64 Presents Preclinical Data 64 Phase 2b Study 64 Mucosal 64 Disease Progression 64 Anidulafungin 64 Cardiotoxicity 64 Enoxaparin 64 attenuated strain 64 Polymerase Inhibitor 64 Patients Treated With 64 Eculizumab 64 CDK inhibitor 64 Novel Mechanism 64 S. pyogenes 64 Phase III Trials 64 Respiratory Virus 64 itraconazole Sporanox 64 Darinaparsin 64 Alocrest 64 Receptor Antagonists 64 Peginterferon Alfa 2a 64 Aflibercept 64 ceftazidime 64 ara C 64 sorafenib Nexavar 64 Vicriviroc 64 Moxifloxacin 64 oritavancin 64 proteasome inhibitor 64 Potent Inhibitor 64 selective modulator 64 Blinatumomab 64 polymerase inhibitors 64 Tumor Necrosis Factor 64 Chronic Hepatitis C 64 Controlled Study 64 Pharmacokinetic PK 64 Immunotherapeutic 64 Antifungal 64 daptomycin 64 Recombinant Human 64 von Willebrand Factor 64 Pivotal Study 64 ganetespib 64 Talabostat 64 Tolerability 64 Double Blind Placebo 64 PEG IFN 63 Glufosfamide 63 Safinamide 63 Kinase Inhibitors 63 Randomized Double blind 63 Placebo Controlled Study 63 Hepatocellular Carcinoma 63 Delafloxacin 63 Guanilib 63 erlotinib Tarceva ® 63 Cytochrome P# 63 Cyclosporine 63 Multimeric 63 Chronic Myeloid Leukemia 63 Immunogenic 63 Preclinical Study 63 Potent Antiviral Activity 63 Nitazoxanide 63 IND Application 63 Systemic Delivery 63 Hepatitis C Virus 63 Plus Ribavirin 63 Melphalan 63 Myelodysplastic Syndromes 63 Kahalalide F 63 Relapsing Multiple Sclerosis 63 Respiratory Syncytial Virus 63 CCX# B 63 AEGR 63 Alinia 63 Antitumor 63 INCB# [003] 63 PEGylated Fab fragment 63 Lacosamide 63 Septic Shock 63 CD# monoclonal antibody 63 evaluating tivozanib 63 Trial Evaluating 63 Itraconazole 63 Colorectal Cancer Patients 63 Prophylactic Treatment 63 Dapagliflozin 63 Extended Release 63 Naive Patients 63 voriconazole 63 generation antisense inhibitor 63 Hepatitis C Virus HCV 63 Presents Preclinical 63 FOLOTYN ® 63 NDA Submission 63 Replacement Therapy 63 inhibitor RG# 63 Study Evaluating 63 Cytotoxic 63 Hedgehog Pathway Inhibitor 63 histone deacetylase HDAC inhibitor 63 CCR5 antagonist 63 Pharmacodynamic 63 tyrosine kinase inhibitor 63 Abstract Number 63 Dose Escalation 63 CD3 monoclonal antibody 63 Anthracycline 63 Personalized Immunotherapy 63 Pivotal Phase 63 nucleoside analogues 63 Parathyroid Hormone 63 Randomized Double Blind Placebo 63 Tocilizumab 63 mertansine 63 Hepatitis B Virus 63 CCX# 63 Laquinimod 63 Civacir 63 Chronic Lymphocytic Leukemia 63 protein kinase inhibitor 63 Demonstrates Efficacy 63 DermaVir Patch 62 Influenza Virus 62 G#DT 62 Fibrinogen 62 PDX pralatrexate 62 Gleevec resistant 62 polymerase inhibitor 62 Files Investigational 62 humanized anti 62 receptor tyrosine kinase inhibitor 62 Antisense 62 Advanced Melanoma 62 Monoclonal 62 Therapeutic Effects 62 Dose Escalation Study 62 Renal Cell Carcinoma 62 Diabetic Nephropathy 62 CEQ# 62 Synthetic Peptide 62 Late Breaker 62 Neulasta ® 62 Demonstrates Positive 62 Telaprevir 62 Phase III Trial 62 invasive candidiasis 62 Significantly Improved 62 Fondaparinux 62 Anticancer Drugs 62 cetuximab Erbitux R 62 Atopic Dermatitis 62 virus HCV protease inhibitor 62 Linagliptin 62 NXL# 62 SPRYCEL ® 62 5 Fluorouracil 62 CTAP# Capsules 62 Initiate Phase 62 Degarelix 62 selective orally bioavailable 62 TRX1 62 CYP#A# CYP#D# 62 Ranolazine 62 nucleotide analog 62 PROSTASCINT R 62 HCV Genotype 62 PSN# [002] 62 huC# DM4 62 Insulin Glargine 62 pharmacokinetic interactions 62 PKC# 62 FDA Accepts 62 Romidepsin 62 VAPRISOL 62 Selective Inhibitor 62 FluCide 62 JAK inhibitor 62 Aptamer 62 Myelofibrosis 62 Initiates Clinical 62 multikinase inhibitor 62 SAR# [004] 62 Cannabinoid 62 Single Dose 62 adalimumab Humira 62 2 methoxyestradiol 62 GW# [003] 62 AEG# 62 Autologous Stem Cell Transplantation 62 Receptor Antagonist 62 thalidomide Thalomid 62 Vivo Efficacy 62 Noxafil 62 Solid Tumors 62 Long Term Efficacy 62 CR# vcMMAE 62 ritonavir boosted 62 Bevirimat 62 Alkaline Phosphatase 62 Unresectable 62 replicon 62 Myelodysplastic Syndrome MDS 62 Nucleoside 62 Small Molecule 62 Treated Patients 62 nucleoside analog 62 bosutinib 62 Viral Suppression 62 Complicated Skin 62 Statistically Significant 62 Efficacious 62 RAV# 62 Clostridium difficile Infection 62 Combination Treatment 62 Fluconazole 62 Cloretazine 62 Toxicities 62 MORAb 62 Temsirolimus 62 Hypercholesterolemia 62 Lubiprostone 62 Elvitegravir 62 Phase 2a Trial 62 linezolid resistant 62 selective antagonist 62 Double Blind Randomized 62 Bevacizumab 62 Hepatitis C Infection 62 novel orally bioavailable 62 Ziprasidone 62 Bezielle 62 PRT# 62 Randomised Trial 62 selective kinase inhibitor 62 Azacitidine 62 Deforolimus 62 Inactivated 62 Severe Sepsis 62 See CLINICAL PHARMACOLOGY 62 MKC# MT 62 Controlled Trial 62 CD# antibody [001] 61 XL# XL# 61 IAP inhibitor 61 Disease Modifying 61 Orally Active 61 selective agonist 61 ketolide antibiotic 61 prucalopride 61 BAY #-# 61 Pivotal Trial 61 Oral Session 61 HGS ETR2 61 Immune Responses 61 OXi# 61 Presents Positive 61 seliciclib 61 Pazopanib 61 Pharmacodynamics 61 Haemophilus b Conjugate 61 targeting CD# 61 Rotavirus Vaccine 61 chimeric monoclonal antibody 61 Cholesterol Lowering Drug 61 murine monoclonal antibody 61 Investigational Agent 61 Nebulized 61 invasive aspergillosis 61 Sipuleucel T 61 atazanavir sulfate 61 RNAi Therapeutics 61 iclaprim 61 Receptor Agonist 61 Gout Drug 61 Monoclonal Antibodies 61 Cancer Vaccines 61 Isavuconazole 61 Respiratory Syncytial Virus RSV 61 Ozarelix 61 amphotericin B 61 Clinical Outcome 61 Adjuvant Treatment 61 Oncolytic 61 II Clinical Trial 61 pegylated 61 Novel Inhibitor 61 Luteinizing Hormone Releasing Hormone 61 Fixed Dose 61 Estrogen Receptor 61 investigational antiplatelet agent 61 Safety Tolerability 61 compound AEZS 61 Teriflunomide 61 Virologic 61 Successfully Completes Phase 61 methicillin resistant S. aureus 61 Inflammatory Arthritis 61 Motavizumab 61 OMP #M# 61 CYT# 61 Fluorouracil 61 trastuzumab DM1 T DM1 61 ZYBRESTAT TM 61 Pertuzumab 61 Lenalidomide 61 Mg Usa 61 Previously Treated 61 rifamycin 61 Velcade bortezomib 61 Archexin 61 AKT inhibitor 61 Olaparib 61 protein tyrosine phosphatase 1B 61 Pegylated Interferon 61 Survival Benefit 61 HCV replicon 61 radiation sensitizer 61 Rigel R# 61 Malignant Melanoma 61 Tacrolimus 61 Phase Ib study 61 Demonstrated Significant 61 ALN TTR 61 Dengue Virus 61 Chronic Myeloid Leukemia CML 61 intravesical instillation 61 NEUGENE 61 bactericidal activity 61 Initiate Clinical Trial 61 administered subcutaneously 61 Drug Resistant 61 Humanized Anti 61 Antibacterials 61 Chronic Hepatitis B 61 HQK 61 caspofungin 61 alpha 2a 61 CYT# potent vascular disrupting 61 Copegus ribavirin 61 UPLYSO 61 Peginterferon alfa 2b 61 Investigational Treatment 61 Aplidin R 61 Immunomodulatory 61 Cell Lymphoma 61 Rheumatoid Arthritis Drug 61 pharmacokinetic PK study 61 Adalimumab 61 Pegylated Liposomal Doxorubicin 61 Onconase 61 superficial bladder cancer 61 Hormone Refractory Prostate Cancer 61 proteasome inhibitors 61 MVA BN R 61 Streptococcus pyogenes 61 DXL# 61 humanized antibody 61 Reports Preclinical Data 61 Oral Mucositis 61 Hepatic Encephalopathy 61 AAG geldanamycin analog 61 milatuzumab 61 Darusentan 61 CANCIDAS 61 PEGylated 61 targeted radiotherapeutic 61 Tanespimycin 61 Reverset 61 Apoptotic 61 Anticancer Drug 61 YONDELIS 61 Diffuse Large B 61 MT# MEDI 61 Completes Patient Enrollment 61 Shows Promising 61 Altastaph 61 Metastatic Prostate Cancer 61 Anticancer Activity 61 Alfacell proprietary ribonuclease 61 Pivotal Trials 61 CBLC# 61 K. pneumoniae 61 PEG SN# 61 Interferon Alfa 61 HCV Protease Inhibitor 60 beta lactamase inhibitor 60 oral JAK1 60 Virus Infection 60 CD# antibodies 60 relapsed MM 60 SCH # 60 Analogs 60 Patients Receiving 60 Aplidin 60 Natalizumab 60 Cyclophosphamide 60 Adjuvanted 60 Genentech Rituxan 60 ENMD # 60 First Patient Dosed 60 glycopeptide 60 S/GSK# 60 cIAI 60 Staphylococcal 60 Macrolide 60 Vancomycin resistant 60 Protease 60 generation cephalosporin antibiotic 60 Allergic Rhinitis 60 Phase Ib Clinical Trial 60 Intravesical 60 injectable investigational 60 FOLFOX6 60 Pharmacokinetics 60 TAKSTA 60 LY# [002] 60 transcriptase inhibitors NNRTIs 60 targeted antifolate 60 Raltegravir 60 Bosentan 60 Interferon beta 1b 60 Rivaroxaban 60 nanoviricides 60 Invasive Fungal Infections 60 Vitaxin 60 Study Showed 60 Achieves Primary Endpoint 60 Omacetaxine mepesuccinate 60 Mipomersen 60 topically administered 60 Gemcitabine 60 #I TM# 60 TRO# 60 highly immunogenic 60 Vidofludimus 60 ALN HPN 60 Randomized Double Blind 60 gefitinib Iressa 60 alfa 2a 60 histone deacetylase inhibitor 60 Metastatic Renal Cell Carcinoma 60 small molecule tyrosine 60 lexidronam injection 60 elvitegravir 60 anti CD3 60 T#I mutant 60 HuMax CD4 60 Initiates Phase 2b 60 Aztreonam 60 Daclizumab 60 Prognostic Significance 60 RGB # 60 octreotide acetate 60 LY# [003] 60 epithelial tumors 60 Chronic Sinusitis 60 Metastatic Colorectal Cancer 60 Therapeutic Antibody 60 JVRS 60 Bacteremia 60 favorable pharmacokinetic profile 60 broad spectrum cephalosporin 60 Inflammatory Diseases 60 Levoleucovorin 60 Tofacitinib 60 HCV protease inhibitor 60 Bazedoxifene 60 Lanthanum Carbonate 60 Transdermal Patch 60 Newly Diagnosed Multiple Myeloma 60 KRN# 60 MAGE A3 ASCI 60 Inhibits 60 pertuzumab 60 Doxil ® 60 Transdermal Delivery 60 Mimetics 60 Pulmonary Arterial Hypertension 60 metastatic malignant 60 Oral Presentation 60 microtubule inhibitor 60 HER2 antibody 60 velafermin 60 nosocomial pneumonia 60 Relapsing Remitting Multiple Sclerosis 60 Bivalirudin 60 tkRNAi 60 depsipeptide 60 VNP#M 60 Receives Orphan Drug Designation 60 non nucleoside HCV 60 oral antiviral 60 alkylating agent 60 ISTODAX ® 60 ertapenem 60 5alpha reductase 60 HuMax EGFr 60 Muraglitazar 60 posaconazole 60 Janus kinase 60 Darunavir 60 Trastuzumab 60 Files IND 60 intranasal formulation 60 Acute Ischemic Stroke 60 triciribine phosphate monohydrate 60 Combination REOLYSIN R 60 Treatment Naive HIV 60 Lenocta TM 60 ganciclovir 60 Gleevec imatinib mesylate 60 JAK1 60 Soft Tissue Sarcoma 60 peripherally acting 60 Pegloticase 60 MDRSP 60 Meta Analysis 60 Somatostatin 60 Hepatotoxicity 60 leukemia CLL 60 uricase 60 PEGASYS ® 60 Proteasome 60 Anticoagulant 60 benzimidazole 60 ATL/TV# 60 Stent Restenosis 60 Refractory Hodgkin Lymphoma 60 Pradefovir 60 mRCC 60 brivanib 60 Entry Inhibitor 60 Prodrug 60 FDA Approvals 60 Prospective Randomized 60 Tumor Targeting 60 MEK inhibitor 60 Preclinical Models 60 Indacaterol 60 neuraminidase inhibitor 60 Tesamorelin 60 Tumor Response 60 Lymphocytic 60 long acting muscarinic 60 Shows Efficacy 60 Methicillin 60 Allogeneic 60 Prophylaxis 60 oral proteasome inhibitor 60 Bare Metal Stent 60 Dose Response 60 Tiotropium 60 Present Preclinical Data 60 thymalfasin 60 OncoVEX GM CSF 60 Interferon alpha 60 Progenitor Cells 60 Novel Therapeutic 60 Piperacillin 60 direct thrombin inhibitors 60 Squalamine 60 beta 1a 60 echinocandins 60 Diabetic Foot Ulcer 60 EGFR HER2 60 BARACLUDE R 60 cidofovir 60 Adjuvant Therapy 59 Symadex 59 RhuDex ® 59 Demonstrates Sustained 59 NS4A 59 JNJ Q2 59 INCB# [001] 59 TNF Tumor Necrosis Factor 59 vitro cytotoxicity 59 quinolone 59 Radiofrequency Ablation RFA 59 refractory gout 59 K#R [002] 59 Lupus Drug 59 Treatment Regimen 59 Radiofrequency Ablation 59 galiximab 59 PSMA ADC 59 Gastrointestinal Stromal Tumors 59 CIMZIA TM 59 Japanese Encephalitis vaccine 59 pharmacokinetic PK profile 59 Rheumatoid Arthritis Patients 59 MGCD# [001] 59 Protein Kinase 59 Zolinza 59 TLR9 agonist 59 Adjunctive Therapy 59 Adenoviral 59 Pharmacokinetic 59 XmAb# 59 Lymphoid 59 Glatiramer Acetate 59 Inactivation 59 metastatic renal cell carcinoma 59 TBC# 59 demonstrated antitumor activity 59 cell lymphoma CTCL 59 ON #.Na 59 Interferon 59 HCV SPRINT 59 FLT3 59 Antiviral 59 Amrubicin 59 elotuzumab 59 IMC A# 59 Morpholino 59 IRX 2 59 pegylated interferon alpha 59 myelodysplastic myeloproliferative diseases 59 Phase 2a Study 59 Azedra 59 pegylated interferons 59 abacavir Ziagen 59 teriflunomide 59 DiLA2 59 BMS# 59 Akt inhibitor 59 Vidaza azacitidine 59 metastatic neuroendocrine tumors 59 ALT normalization 59 Alemtuzumab 59 atovaquone 59 p# biomarker 59 STRIDE PD 59 BARACLUDE ® 59 dasatinib Sprycel 59 MGd 59 preclinical efficacy 59 Smooth Muscle 59 miconazole Lauriad ® 59 Exemestane 59 Cervical Dysplasia 59 talabostat 59 Carbamazepine 59 selective inhibition 59 Severe Asthma 59 Disease Severity 59 Entecavir 59 oral renin inhibitor 59 HoFH 59 Valortim ® 59 panitumumab Vectibix 59 rilonacept 59 HDACi 59 ribavirin RBV 59 Relapsed Refractory 59 Vildagliptin 59 Tolvaptan 59 Pimavanserin 59 Thrombin 59 Panzem R NCD 59 Brain Metastases 59 HGS ETR1 59 include Phenoptin TM 59 FVIIa 59 Eluting Stent 59 ergot derivatives 59 annexin V 59 Shows Statistically Significant 59 assay detects 59 Camptosar ® 59 CRMD# 59 antisense inhibitor 59 candidemia 59 PegIFN RBV 59 Improved Survival 59 ECCMID 59 decitabine 59 Histone Deacetylase 59 Clusterin 59 generation Hsp# inhibitor 59 PI3K inhibitor 59 viral kinetics 59 Malignant Glioma 59 leukemia AML 59 R roscovitine 59 Mycophenolate Mofetil 59 Pruvel 59 selective adenosine 59 Cathepsin S 59 nucleotide analogue 59 Efficacy Trial 59 Enterococcus faecium 59 Chlamydia trachomatis 59 C Reactive Protein 59 stable nucleic acid 59 huN# DM1 59 nilotinib 59 Adjuvant Chemotherapy 59 Protein Expression 59 immunostimulatory 59 Phase Ib clinical 59 gastrointestinal stromal tumors GIST 59 immunomodulatory 59 GMX# 59 Resistant Hypertension 59 PNP inhibitor 59 Initiates Clinical Trial 59 Panzem NCD 59 Fludarabine 59 NeoLipid R 59 vinca alkaloid 59 Hemodialysis Patients 59 toenail onychomycosis 59 novel peptide 59 telaprevir VX 59 systemic RNAi therapeutic 59 SPIRIVA ® 59 Initiates Phase II 59 Randomized Clinical Trial 59 Silodosin 59 Xelox 59 intravenous recombinant 59 Interferon Alpha 59 Regenerative Cells 59 Pemetrexed 59 TNF Alpha 59 Microspheres 59 pomalidomide 59 Cutaneous T 59 Drug Shows Promise 59 Ganciclovir 59 hypereosinophilic syndrome 59 busulfan 59 Neisseria gonorrhoeae 59 Albuferon TM 59 cMET 59 oral antifungal 59 Inhalation Solution 59 Percutaneous Tibial Nerve Stimulation 59 pharmacodynamic properties 59 BiTE 59 Celecoxib 59 etanercept Enbrel 59 Vancomycin 59 Patient Outcomes 59 Fluticasone 59 Initiates Enrollment 59 administered intramuscularly 59 Receives Approvable Letter 59 Genotypes 59 Leukemias 59 Saquinavir 59 pharmacokinetic PK 59 liposome injection 59 Candida infections 59 biologic therapy 59 Poster Presentation 59 LymphoStat B belimumab 59 ESBA# 59 phase III isavuconazole 59 Nanobody 59 Bacterial Infections 59 Signaling Pathway 59 Vaprisol 59 plasma pharmacokinetics 59 Preclinical Evaluation 59 tipifarnib 59 UGT#A# 59 efavirenz EFV 59 Enterobacter cloacae 59 Escherichia coli Klebsiella pneumoniae 59 Bioequivalence 59 Cancidas 59 EndoTAG TM -1 59 Endometrial Cancer 59 chemotherapy induced neutropenia 59 Phase III Pivotal Trial 59 mycophenolate mofetil 59 oral rivaroxaban 59 ZEVALIN ® 59 Molecular Diagnostic 59 novel prodrug 59 S. aureus isolates 59 tazobactam 59 antisense oligonucleotide 59 Clinical Trial Evaluating 59 HER1 59 DAS# [001] 59 panobinostat 59 Idiopathic Pulmonary Fibrosis 58 AMPA kainate 58 nelfinavir Viracept 58 Ad5FGF 4 58 Aptivus ® 58 MyVax R 58 Exelixis XL# 58 alfa 2b 58 oral nucleoside analogue 58 quinolones 58 NS5B polymerase 58 nitazoxanide 58 Confirmatory 58 INGN 58 Human Monoclonal Antibody 58 alefacept 58 JAK2 Inhibitor 58 Patients Treated 58 JAK2 inhibitor 58 Lenocta 58 highly selective inhibitor 58 Improves Survival 58 Endothelial Cells 58 Attenuates 58 metastatic RCC 58 Leukine ® 58 HCV polymerase 58 Statin Therapy 58 Retroviral 58 Lamotrigine 58 HCV RESPOND 2 58 dexamethasone Decadron 58 Immunosuppression 58 TMC# [002] 58 Protease Inhibitors 58 PTP 1B 58 Plasmid DNA 58 candidiasis 58 MAb 58 Candida albicans 58 antibody blinatumomab MT#/MEDI-# 58 piperacillin tazobactam 58 A3 adenosine receptor 58 Protein Kinase C 58 Conjugate Vaccine 58 LT NS# 58 Diabetic Neuropathy 58 Neoadjuvant 58 Paclitaxel Carboplatin 58 Hepatitis C Patients 58 antiviral efficacy 58 enterococcal 58 imipenem 58 Adenoma 58 Angiotensin Converting Enzyme 58 Refractory Angina 58 VP# [004] 58 Oligonucleotides 58 small molecule chemotherapeutic 58 ibritumomab tiuxetan 58 SYN# 58 Randomized Study 58 Effectively Treats 58 NRTI resistance 58 Targeted Therapy 58 Kinoid 58 Annamycin

Back to home page